{"filing":{"accession_number":"0001140361-26-024949","cik":"0001348911","ticker":"KALV","company_name":"KalVista Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"ny20075902x2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/ny20075902x2_8k.htm"},"events":[{"id":5316,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"KalVista Pharmaceuticals completed a merger with a Parent entity on June 11, 2026, resulting in a change of control. The transaction included a tender offer and modification of convertible note terms to provide cash conversion rights at $27.00 per share, with the Parent acquiring control of the Company effective at the Effective Time.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6387,"accession_number":"0001140361-26-024949","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a Supplemental Indenture in connection with a \"Merger\" effective upon the \"Effective Time,\" which constitutes a material acquisition or change of control event. The supplemental indenture modifies convertible note terms to provide cash conversion rights at a specified merger consideration ($27.00 per share), indicating a completed or imminent merger transaction that materially affects the company's capital structure and security holders' rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6388,"accession_number":"0001140361-26-024949","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses termination of equity incentive plans and an employee stock purchase plan in connection with the \"consummation of the Offer and the Merger\" and the \"Effective Time,\" which are hallmarks of a merger or acquisition completion. While Item 1.02 technically covers termination of material agreements, the context here is the closing of an M\u0026A transaction, making the underlying M\u0026A activity the material event. The termination of these plans is a consequence of the merger's consummation, not the primary event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6389,"accession_number":"0001140361-26-024949","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 explicitly addresses \"Completion of Acquisition or Disposition of Assets\" and incorporates disclosures from Item 3.01 (Change in Control) and Item 5.01 (Changes in the Registrant's Certifying Accountant), indicating a material M\u0026A transaction has been completed. This is a core M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6393,"accession_number":"0001140361-26-024949","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses the consummation of a merger and tender offer resulting in a change of control of KalVista Pharmaceuticals. The language \"consummation of the Offer and the Merger\" and \"Parent, as the direct parent of Purchaser, acquired control of the Company\" clearly indicates completion of a material acquisition/change of control transaction. This is a terminal M\u0026A event affecting the registrant's ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6396,"accession_number":"0001140361-26-024949","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a merger between KalVista Pharmaceuticals and a Parent entity on June 11, 2026. Although disclosed under Item 7.01 (Other Events) rather than the typical Item 2.01, the substance is a material acquisition/change of control event. The joint press release announcement of merger completion is a definitive M\u0026A milestone that would materially affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5317,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Following completion of the merger, KalVista notified Nasdaq on June 10–11, 2026 of the consummation and requested delisting of its shares from The Nasdaq Global Market. Trading was halted effective June 10, 2026 and ceased on June 11, 2026, with the Company intending to file Form 25 and Form 15 to remove listing and terminate SEC registration.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6391,"accession_number":"0001140361-26-024949","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that KalVista notified Nasdaq on June 10–11, 2026 of the consummation of a merger and requested delisting of its shares from The Nasdaq Global Market, with trading halted effective June 10, 2026 and shares ceasing trading on June 11, 2026. The company intends to file Form 25 to remove listing and Form 15 to terminate SEC registration and reporting obligations. This is a material delisting event triggered by a merger consummation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5318,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"summary":"Eight directors (Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor, and Edward W. Unkart) resigned from the Company's board and all committees effective immediately in connection with the merger consummation, with no disagreement cited.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6394,"accession_number":"0001140361-26-024949","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"The filing discloses the resignation of eight directors (Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor, and Edward W. Unkart) from the Company's board and all committees in connection with a merger, effective immediately. While the section also describes John Hess becoming the sole director and an officer, and compensatory arrangements for executives, the principal disclosed action is the departure of the entire prior board. The filing explicitly states these resignations were not due to disagreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5319,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"2.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"The filing discloses creation of a direct financial obligation under Item 2.03, incorporating Item 1.01 by reference; the specific nature of the obligation (debt, lease, contingent liability, or other commitment) cannot be determined without access to the referenced Item 1.01 content.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6390,"accession_number":"0001140361-26-024949","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the section merely incorporates Item 1.01 by reference without providing substantive detail. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined—it could relate to debt, lease arrangements, contingent liabilities, or other financial commitments. The incorporation-by-reference structure prevents precise classification into debt-specific categories (covenant_breach, ma_activity, etc.), warranting a conservative other_material classification pending review of the referenced Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5320,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"3.03","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"summary":"Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01, 5.01, and 5.03; the specific nature of the modification cannot be reliably determined from the cross-references alone, though it likely relates to the merger, delisting, or change of control.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6392,"accession_number":"0001140361-26-024949","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01 (delisting risk), 5.01 (changes in control), and 5.03 (amendments to articles/bylaws). Without the full text of those incorporated items, the specific nature of the modification cannot be determined. The cross-references suggest a significant corporate event (possibly delisting, change of control, or charter amendment), but the actual event type cannot be reliably classified from this summary alone. Marked as material given the Item 3.03 designation and cross-references to control-related items.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5321,"run_id":4659,"accession_number":"0001140361-26-024949","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"summary":"The Company's certificate of incorporation and bylaws were completely amended and restated effective at the Effective Time; no substantive detail is provided regarding the changes, suggesting these are routine administrative amendments incidental to the merger transaction.","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11","submitted_at":null,"items":[{"id":6395,"accession_number":"0001140361-26-024949","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The disclosure describes a complete amendment and restatement of both the certificate of incorporation and bylaws effective at a specified time. While such governance changes are formally required to be disclosed under Item 5.03, the filing provides no substantive detail about what changed or why, suggesting these are routine administrative amendments likely incidental to a larger transaction (possibly a merger or recapitalization referenced by \"Effective Time\"). Without evidence of material governance changes affecting investor rights or company operations, this appears to be a routine filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6387,"accession_number":"0001140361-26-024949","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses entry into a Supplemental Indenture in connection with a \"Merger\" effective upon the \"Effective Time,\" which constitutes a material acquisition or change of control event. The supplemental indenture modifies convertible note terms to provide cash conversion rights at a specified merger consideration ($27.00 per share), indicating a completed or imminent merger transaction that materially affects the company's capital structure and security holders' rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6388,"accession_number":"0001140361-26-024949","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses termination of equity incentive plans and an employee stock purchase plan in connection with the \"consummation of the Offer and the Merger\" and the \"Effective Time,\" which are hallmarks of a merger or acquisition completion. While Item 1.02 technically covers termination of material agreements, the context here is the closing of an M\u0026A transaction, making the underlying M\u0026A activity the material event. The termination of these plans is a consequence of the merger's consummation, not the primary event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6389,"accession_number":"0001140361-26-024949","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 explicitly addresses \"Completion of Acquisition or Disposition of Assets\" and incorporates disclosures from Item 3.01 (Change in Control) and Item 5.01 (Changes in the Registrant's Certifying Accountant), indicating a material M\u0026A transaction has been completed. This is a core M\u0026A activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6390,"accession_number":"0001140361-26-024949","item_number":"2.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the section merely incorporates Item 1.01 by reference without providing substantive detail. Without access to Item 1.01's content, the specific nature of the obligation cannot be determined—it could relate to debt, lease arrangements, contingent liabilities, or other financial commitments. The incorporation-by-reference structure prevents precise classification into debt-specific categories (covenant_breach, ma_activity, etc.), warranting a conservative other_material classification pending review of the referenced Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6391,"accession_number":"0001140361-26-024949","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that KalVista notified Nasdaq on June 10–11, 2026 of the consummation of a merger and requested delisting of its shares from The Nasdaq Global Market, with trading halted effective June 10, 2026 and shares ceasing trading on June 11, 2026. The company intends to file Form 25 to remove listing and Form 15 to terminate SEC registration and reporting obligations. This is a material delisting event triggered by a merger consummation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6392,"accession_number":"0001140361-26-024949","item_number":"3.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01 (delisting risk), 5.01 (changes in control), and 5.03 (amendments to articles/bylaws). Without the full text of those incorporated items, the specific nature of the modification cannot be determined. The cross-references suggest a significant corporate event (possibly delisting, change of control, or charter amendment), but the actual event type cannot be reliably classified from this summary alone. Marked as material given the Item 3.03 designation and cross-references to control-related items.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6393,"accession_number":"0001140361-26-024949","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses the consummation of a merger and tender offer resulting in a change of control of KalVista Pharmaceuticals. The language \"consummation of the Offer and the Merger\" and \"Parent, as the direct parent of Purchaser, acquired control of the Company\" clearly indicates completion of a material acquisition/change of control transaction. This is a terminal M\u0026A event affecting the registrant's ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6394,"accession_number":"0001140361-26-024949","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"The filing discloses the resignation of eight directors (Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor, and Edward W. Unkart) from the Company's board and all committees in connection with a merger, effective immediately. While the section also describes John Hess becoming the sole director and an officer, and compensatory arrangements for executives, the principal disclosed action is the departure of the entire prior board. The filing explicitly states these resignations were not due to disagreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6395,"accession_number":"0001140361-26-024949","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"The disclosure describes a complete amendment and restatement of both the certificate of incorporation and bylaws effective at a specified time. While such governance changes are formally required to be disclosed under Item 5.03, the filing provides no substantive detail about what changed or why, suggesting these are routine administrative amendments likely incidental to a larger transaction (possibly a merger or recapitalization referenced by \"Effective Time\"). Without evidence of material governance changes affecting investor rights or company operations, this appears to be a routine filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"},{"id":6396,"accession_number":"0001140361-26-024949","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a merger between KalVista Pharmaceuticals and a Parent entity on June 11, 2026. Although disclosed under Item 7.01 (Other Events) rather than the typical Item 2.01, the substance is a material acquisition/change of control event. The joint press release announcement of merger completion is a definitive M\u0026A milestone that would materially affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:45:30.482463+00:00","company_name":"KalVista Pharmaceuticals, Inc.","ticker":"KALV","filing_date":"2026-06-11"}]}